<DOC>
	<DOCNO>NCT01702064</DOCNO>
	<brief_summary>This study design determine maximal tolerate dose Ruxolitinib combination nilotinib patient chronic myeloid leukemia ( CML ) .</brief_summary>
	<brief_title>Ruxolitinib Combination With Nilotinib Chronic Myeloid Leukemia ( CML ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>Must chronic phase chronic myeloid leukemia ( CML ) . They must also treatment nilotinib either first , second , thirdline therapy . Must complete cytogenetic response ( CCyR ) OR must nilotinib minimum 6 month . Must undergone treatment form cancer ( aside nonmelanoma skin cancer ) past 5 year . 18 year age old must able speak read English Spanish . Able provide inform consent . Prior therapy tyrosine kinase inhibitor ( TKI ) nilotinib allowable , however , nilotinib must current therapy . All participant must care Moffitt Cancer Center physician , enrollment expect complete within 6 month . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 ( Karnofsky ≥60 % . Must normal organ marrow function define study protocol . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant partner participate study , inform treat physician immediately . Men treat enrol protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion Ruxolitinib nilotinib administration . Women childbearing age require negative pregnancy test within 14 day enrol study . Ability understand willingness sign write informed consent document BHCG perform woman childbearing potential screening prior enrollment trial . STAT3 level bone marrow also measure prior enrollment . Patients accelerate phase blast phase CML . May receive investigational agent . History allergic reaction attribute compound similar chemical biologic composition ruxolitinib agent use study . Known history prolong QT interval ( QTc &gt; 480 ) . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study . Women breast feeding infant discontinue practice mother treat ruxolitinib . Currently receive drug consider strong CYP3A4 inducer inhibitor discontinue changed alternative drug prior enrol trial . HIVpositive patient receive combination antiretroviral therapy exclude study . Patients receive nilotinib 200 mg mouth , twice day ( PO BID ) low dose eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CML</keyword>
	<keyword>CP-CML</keyword>
	<keyword>Chronic Phase-CML ( CP-CML )</keyword>
	<keyword>chronic myeloid leukemia</keyword>
</DOC>